Literature DB >> 11030452

Acute behavioural disturbances related to imaging studies and outcome in mild-to-moderate head injury.

J van der Naalt1, A H van Zomeren, W J Sluiter, J M Minderhoud.   

Abstract

The frequency of behavioural disturbances early after injury in relation to outcome was prospectively investigated in a series of 67 patients with mild-to-moderate head injury (as defined by GCS on admission). In more than half of the patients, behavioural disturbances were observed. Restlessness occurred in 40% of patients, whereas agitation was seen in 19% of patients. In all patients, restlessness and agitation disappeared before resolution of PTA. In multiple regression analysis, restlessness and PTA were found to be separate factors in predicting outcome. On imaging studies, twice as many lesions were seen in patients with restlessness and agitation (81% compared to 39%), mainly localized in the frontotemporal region. In two thirds of patients with early behavioural disturbances, residual emotional and cognitive impairments were seen 1 year after injury. This study suggests that behavioural disturbances in the early phase after injury are related to frontotemporal lesions and lends support for the view of the existence of a separate profile of patient behaviour in mild-to-moderate head injury.

Entities:  

Mesh:

Year:  2000        PMID: 11030452     DOI: 10.1080/026990500421895

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  8 in total

1.  Validating Multidimensional Outcome Assessment Using the TBI Common Data Elements: An Analysis of the TRACK-TBI Pilot Sample.

Authors:  Lindsay D Nelson; Jana Ranson; Adam R Ferguson; Joseph Giacino; David O Okonkwo; Alex Valadka; Geoffrey Manley; Michael McCrea
Journal:  J Neurotrauma       Date:  2017-06-08       Impact factor: 5.269

2.  Diagnosing the GOSE: Structural and Psychometric Properties Using Item Response Theory, a TRACK-TBI Pilot Study.

Authors:  Jana Ranson; Brooke E Magnus; Nancy Temkin; Sureyya Dikmen; Joseph T Giacino; David O Okonkwo; Alex B Valadka; Geoffrey T Manley; Lindsay D Nelson
Journal:  J Neurotrauma       Date:  2019-05-23       Impact factor: 5.269

Review 3.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

4.  Abnormalities on magnetic resonance imaging seen acutely following mild traumatic brain injury: correlation with neuropsychological tests and delayed recovery.

Authors:  David G Hughes; Alan Jackson; Damon L Mason; Elizabeth Berry; Sally Hollis; David W Yates
Journal:  Neuroradiology       Date:  2004-06-08       Impact factor: 2.804

Review 5.  Interrelation between Neuroendocrine Disturbances and Medical Complications Encountered during Rehabilitation after TBI.

Authors:  Caroline I E Renner
Journal:  J Clin Med       Date:  2015-09-22       Impact factor: 4.241

6.  Pharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysis.

Authors:  David R Williamson; Anne Julie Frenette; Lisa Burry; Marc M Perreault; Emmanuel Charbonney; François Lamontagne; Marie-Julie Potvin; Jean-François Giguère; Sangeeta Mehta; Francis Bernard
Journal:  Syst Rev       Date:  2016-11-17

7.  Pharmacological interventions for agitated behaviours in patients with traumatic brain injury: a systematic review.

Authors:  David Williamson; Anne Julie Frenette; Lisa D Burry; Marc Perreault; Emmanuel Charbonney; Francois Lamontagne; Marie-Julie Potvin; Jean-Francois Giguère; Sangeeta Mehta; Francis Bernard
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

8.  Neuropsychiatric Presentations due to Traumatic Brain Injury in Cognitively Normal Older Adults.

Authors:  Jahnavi Mundluru; Abdul Subhan; Tsz Wai Bentley Lo; Nathan Churchill; Luis Fornazzari; David G Munoz; Tom A Schweizer; Corinne E Fischer
Journal:  J Neurotrauma       Date:  2020-10-20       Impact factor: 5.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.